MyFinsight
Home
Blog
About
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$842K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Change in fair value of derivati...
Accrued interest on convertible ...
Net proceeds from issuance of co...
Others
Negative Cash Flow Breakdown
Net loss
Net proceeds from convertible li...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-9,113
-5,046
-5,500
-8,184
Amortization of right to use asset
-
-
53
-
Stock-based compensation expense
963
686
195
496
Amortization of right to use lease asset
4
0
-
0
Non-cash interest expense
158
156
183
215
Change in fair value of derivative liabilities
3,156
-983
220
2,205
Prepaid expenses and other assets
-74
-140
479
-467
Accounts payable, accrued expenses and other liabilities
472
-662
-2,458
-345
Accrued interest on convertible debt - related party
1,847
1,831
1,756
1,604
Net cash from operating activities
-2,439
-3,866
-6,042
-3,542
Net cash from investing activities
-
-
0
-
Net proceeds from convertible line of credit related party
-257
257
10,000
0
Net proceeds from issuance of common stock
1,294
-
1,164
853
Net proceeds from exercise of stock options and warrants
560
-
1,073
443
Net cash flows from financing activities
1,597
257
12,237
1,296
Net decrease in cash and cash equivalents
-842
-3,609
6,195
-2,246
Cash and cash equivalents, beginning of period
14,111
17,720
11,525
15,120
Cash and cash equivalents, end of period
13,269
14,111
17,720
11,525
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net proceeds from
issuance of common stock
$1,294K
(6.24%↑ Y/Y)
Net proceeds from
exercise of stock options...
$560K
(-22.65%↓ Y/Y)
Net cash flows from
financing activities
$1,597K
(-87.66%↓ Y/Y)
Canceled cashflow
$257K
Net decrease in cash
and cash...
-$842K
(37.58%↑ Y/Y)
Canceled cashflow
$1,597K
Change in fair value of
derivative liabilities
$3,156K
(181.53%↑ Y/Y)
Accrued interest on
convertible debt - related...
$1,847K
(-35.76%↓ Y/Y)
Stock-based compensation
expense
$963K
(-0.52%↓ Y/Y)
Accounts payable,
accrued expenses and...
$472K
(114.57%↑ Y/Y)
Non-cash interest
expense
$158K
(-77.30%↓ Y/Y)
Prepaid expenses and
other assets
-$74K
(82.71%↑ Y/Y)
Amortization of right to use
lease asset
$4K
(-66.67%↓ Y/Y)
Net proceeds from
convertible line of credit ...
-$257K
(-102.34%↓ Y/Y)
Net cash from
operating activities
-$2,439K
(82.93%↑ Y/Y)
Canceled cashflow
$6,674K
Net loss
-$9,113K
(46.87%↑ Y/Y)
Buy us a coffee